Eli Lilly & Co. vs. Xenon Pharmaceuticals Inc
Eli Lilly & Co. and Xenon Pharmaceuticals Inc are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| LLY | XENE | |
|---|---|---|
| Market Cap | $1.09 trillion | $6.31 billion |
| Revenue (TTM) | — | — |
| Net Income (TTM) | — | $-409,195,000 |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | XENE | |
|---|---|---|
| Price / Book | — | 5.08 |
LLY and XENE split the valuation factors evenly.
Profitability
| LLY | XENE | |
|---|---|---|
| Return on Equity | — | -32.94% |
LLY and XENE split the profitability factors evenly.
Risk & Sentiment
| LLY | XENE | |
|---|---|---|
| Short Interest | 1.29% | 0.15% |
XENE leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, XENE overview, XENE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.